Contents
The WHO ruled that CBD is not addictive, not harmful to health and has potential therapeutic properties.
On 3 December 2020, the WHO surprisingly recognised the benefits of CBD and endorsed its medicinal use. After a surprise and close vote until the last second, one of the most consumed psychotropics at an international level, has been considered advantageous. Or at least, one of its active ingredients such as CBD.
The WHO ruled that CBD is not addictive, not harmful to health and has potential therapeutic properties.
At Bove Health, we have decided to echo this fact.
The WHO's Commission on Narcotic Drugs and most of the countries that comprise it have achieved a historic event. After a vote in which they obtained the maximum possible number of votes, they generated the endorsement to defer marijuana from their list of controls. As a result, a whole debate has been opened... Is it the right decision?
The use of cannabis as a medicine had been truncated by the refusal of many countries. However, after this event, of the 59 countries participating in the Commission on Narcotic Drugs, there were 27 votes in favour. Thanks to the abstention of other participants, they narrowly overcame the 25 votes against.
As a result, the perception of cannabis will begin to change from now on, with medical use being touted. Even so, there is still a lot of ground to be covered, so this is not the adjudication of the war.
Desde el año 2019, ya venía asomando la idea de la legalización del cannabis dentro de las filas de la OMS. Durante el transcurso de ese año, la OMS promulgó un comunicado con los 6 beneficios del CBD más comprobados en la actualidad.
On this basis, the idea of removing this active ingredient from the list of controls of the United Nations Organisation was launched. Obviously, behind this premise was the contribution of the aforementioned WHO Commission on Narcotic Drugs.
Although several countries on the commission claimed that the use of CBD as a medicine was productive, there was still room for improvement. The other half of the members argued that it was too early to draw an accurate conclusion. The main reason was attributed to the fact that cannabis was still a controversial substance, with inconclusive studies.
However, the WHO's democratic decision has left a sea of mixed opinions. After the vote, representatives from Ecuador and the United States have argued that it is only the first step.
At the same time, they have made it clear that the benefits of CBD should only be used in the medical field. Although the vote was won, the favoured side has been very adamant about strict medicinal use. They have even demanded that the WHO set up a commission to issue guidelines for the proper long-term medicinal use of this active ingredient.
Now that the benefits of CBD are recognised, it is necessary to clarify the premise as such. CBD, or cannabidiol, is considered by the WHO as a non-psychotropic product for medicinal purposes. That is, it is the component or active ingredient that has been approved, not cannabis as such.
In short, the commercialisation of cannabis is still subject to the regulations of each country. What has been upheld is the recognition of CBD, a derivative of cannabis, as a medicinal component suitable for mankind.
Summary of diseases for which CBD may have therapeutic benefits taken from Pisanti et al (2017)
Cannabidiol use is commonly performed under the following conditions a personalised therapy according to the needs of each individual and the reason for use in each specific case, taking into account the regulatory framework of each country, as in some places sublingual use is legal and in others it is not. As a general rule, the cannabinoid known as CBD has no known adverse effects at any therapeutic dose, although this does not rule out the existence of certain pharmacological interactions to be considered.
The action of the active ingredient depends mainly on its bioavailability in the body, the absorption process of the active substance being CBD the most influential. In this case, oral or sublingual release means that the action takes longer (the effect does not begin until 30-90 minutes) and is likewise more prolonged (up to approximately 4 hours). Topical administration has a specific action on the tissue where it is applied, and can be beneficial for the treatment of inflammatory skin diseases such as: Scarring, eczema, psoriasis and acne.
Thanks to the high percentage of scientific literature published in recent years, such as clinical and pre-clinical trials that have taken place on the effect of CBD on different pathologies, a combined use is recommended: oral and topical, to maximise the therapeutic effects of Cannabis.. Se recomienda estructurar la toma del CBD durante el día. Mañana-Tarde-Noche, donde la biodisponibilidad es mucho mayor que una única toma.
Another point made in the analysis of the WHO document is that, in general, CBD is well toleratedwith a good safety profile. CBD does not produce the effects usually seen with other cannabinoids such as THC.
The potential adverse health effects of CBD have been extensively reviewed. In general, CBD has been found to have relatively low toxicity, although not all potential effects have been explored. If you want to learn more about the possible side effects that CBD could have, in the WHO report relevant findings from in vitro and animal studies are reported.
Natural | Vegan | Cruelty-Free | Locally Produced